2025-05-20-Jefferies-萨纳（SANA）_深入探讨低免疫细胞治疗领域-_SANA如何脱颖而出并向前发展_19页_4mb

Sana Biotechnology: Equity Research Summary

Company Overview:
Sana Biotechnology is a clinical-stage biotech firm developing hypoimmune cell therapies using its proprietary HIP (Hypoimmune Editing Platform) to engineer cells that evade immune rejection. The platform involves three key genetic modifications: knockout of HLA-I/II genes and overexpression of CD47, selected through extensive preclinical testing to maximize immune evasion. Key applications include Type 1 Diabetes (T1D), autoimmune diseases, and oncology.

Investment Recommendation:
Jefferies rates Sana as "BUY" with a 12-month price target of $7.00, representing a 317% upside from the current price of $1.68. The report models peak revenues of $2.8 billion for the T1D asset (SC451), with scenarios ranging from a base case ($7 price target) to upside (+733% to $14) and downside (-40% to $1), based on program success, regulatory hurdles, and competition.

Recent Clinical Data:

• Positive 12-week follow-up data from an investigator-sponsored UP421 study in a single Type 1 Diabetes patient showed sustained C-peptide levels, indicating functional survival of transplanted cells. Future updates expected in 2025.
• The HIP platform demonstrates immune evasion in vitro, using NK cell assays and gene edits, with data from UP421 supporting clinical translation. IND filing for the iPSC-derived HIP program is on track for 2026.

Competitive Landscape:
Sana's platform advances faster than key competitors:

• CRISPR Therapeutics (CTX211) uses six edits, including HLA knockout but with higher risks of immune clearance due to more modifications. Lags in clinical progress.
• Vertex Pharmaceuticals and others have limited public data, but VRTX's hypoimmune stem cell therapy is in research phase. Academic labs and other studies show inconsistent results due to methodological and genetic differences, not undermining Sana's approach.
• Sana's specific edits (blanket CD47 expression) may offer superior innate immune evasion compared to alternatives.

Key Risks and Catalysts:

• Risks: Efficacy and safety concerns; potential immune rejection; clinical trial failures; manufacturing complexities; competition.
• Catalysts: Long-term UP421 follow-up data (2025), SC451 IND filing (2026), additional safety/toleration data. Patient diversity in trials is a noted question for management.
• Reputational/Operational Issues: Employee engagement, product quality; historical issues highlighted but not deemed material to financial projections.

Valuation:
Based on Discounted Cash Flow (DCF) and probability-adjusted models. Jefferies factors in revenue projections (e.g., $7–14 billion peak for T1D drug) and pipeline value assessments. Analysts emphasize risks like data replication from preclinical variability but reaffirm Sana's innovation.

Upcoming Events:

• Q1 2025 data updates; IND filings in 2026; monitoring for adverse events over extended periods.